Medical device maker Boston Scientific Corporation (NYSE: BSX) reported financial results for the second quarter of 2023. The company also provided guidance for fiscal 2023.
- The company reported net sales of $3.599 billion for Q2, representing an 11% year-over-year increase, and an 11.6% growth on an organic basis
- Net income attributable to stockholders, on an unadjusted basis, was $261 million, compared to $246 million in the year-ago period
- Net income per share came in at $0.18 per share, slightly higher than the $0.17 per share reported last year
- Second-quarter adjusted earnings increased to $0.53 per share from $0.44 per share in the same period of last year
- The management expects net sales to grow in the range of 10.5% to 11.5% in fiscal 2023 on a reported basis, and 10-11% on an organic basis
- Full-year net income, including special items, is expected to be between $0.87 per share and $0.93 per share; the forecast for adjusted EPS is $1.96-$2.00
Most Popular
Key highlights from Eli Lilly’s (LLY) Q1 2024 earnings results
Eli Lilly and Company (NYSE: LLY) reported first quarter 2024 earnings results today. Worldwide revenue was $8.77 billion, up 26% from the year-ago quarter, driven by increases of 16% in
PYPL Earnings: PayPal reports higher revenue and profit for Q1 2024
PayPal Holdings Inc. (NASDAQ: PYPL) announced financial results for the first quarter of 2024, reporting an increase in revenues and adjusted profit. The top line also exceeded analysts' estimates. First-quarter
MCD Earnings: Key quarterly highlights from McDonald’s Q1 2024 financial results
McDonald's Corporation (NYSE: MCD) reported first quarter 2024 earnings results today. Revenues increased 5% year-over-year to $6.1 billion. Revenue growth was 4% in constant currencies. Net income grew 7% to
